News

Sarepta shares slide again as drugmaker bows to FDA pressure to pause gene therapy
Sarepta Therapeutics is pausing shipments of its gene therapy for muscular dystrophy following several patient deaths that ...
Hair transplant vs hair restoration: What’s the difference?
Confused about hair transplant vs hair restoration? Learn the key differences, benefits, and which option might be right for ...
Novo Nordisk's Moat Is Deeper Than You Think
Novo Nordisk holds 72% international and 50%+ U.S. market share in GLP-1 treatments, serving 46 million patients globally.
Replimune Shares Plumb All-Time Lows After FDA Rejection
Replimune shares collapsed on Tuesday after the U.S. Food and Drug Administration rejected the clinical-stage biotechnology company's proposed advanced melanoma treatment. Shares of the Woburn, Mass., ...
Costco customers claim their milk doesn’t spoil for weeks after expiration date — here’s the surprising reason why
Milk from herds with lesser somatic cell counts usually stays fresh longer, according to the Penn State Extension, so if your ...
STAT1h
Pharmalittle: We’re reading about Sarepta conceding to the FDA, the U.S. transplant system, and more
Sarepta Therapeutics reversed course and agreed to halt all shipments of Elevidys, its gene therapy for Duchenne muscular ...